Steroid Agents - Revision history

Caramolly: /* Pharmacological Considerations */

2013-04-15T23:23:08Z

Pharmacological Considerations

Caramolly: /* Introduction */

2013-04-15T23:12:21Z

Introduction

Caramolly: /* Cardiovascular Effects */

2013-04-15T23:10:11Z

Cardiovascular Effects

Caramolly: /* Respiratory Effects */

2013-04-15T23:08:16Z

Respiratory Effects

Caramolly: /* Other Effects */

2013-04-15T23:05:17Z

Other Effects

Bara at 17:32, 24 May 2011

2011-05-24T17:32:38Z

Bara at 16:33, 25 January 2011

2011-01-25T16:33:04Z

Bradlo at 21:59, 2 December 2010

2010-12-02T21:59:31Z

A.allison at 15:03, 1 September 2009

2009-09-01T15:03:06Z

Hstenning at 13:13, 16 April 2009

2009-04-16T13:13:04Z

@@ Line 6: / Line 6: @@
 ==Pharmacological Considerations==
-Alfaxalone is available as either a single agent solution at 10mg/ml, or in combination with alfadolone with polyoxyethylated castor oil as a solvent. Alfaxalone can be administered intravenously and intramuscularly, though the efficacy of intramuscular injection is species dependant - '''do not''' rely on intramuscular injection of alfaxalone to sedate or induce anaesthesia in dogs. It has a rapid onset of action, inducing anaesthesia with 30-60 seconds when given intravenously. Its duration of action is dose dependent.  If given intramuscularly, onset of anaesthesia is within 7-10 minutes.  Recovery occurs due to a combination of metabolism via and redistribution.
+Alfaxalone is water-insoluble, and was first available in combination with the similar molecule alfadolone solubilised in polyoxyethylated castor oil (Cremophor EL) for use in humans, cats and dogs. A newer formulation of alfaxalone (without alfadolone) solubilised in cyclodextrin is available for dogs and cats.
 The formulation of alfaxalone in cyclodextrin has a volume of distribution after a single injection of a clinical dose in dogs and cats of 2.4 L/kg and 1.8 L/kg, respectively. In cats, the mean terminal plasma elimination half-life (t1/2) for alfaxalone is approximately 45 minutes for a 5 mg/kg dose. Mean plasma clearance for a 5 mg/kg dose is 25.1 ± 7.6 mL/kg/min. In dogs, the mean terminal plasma elimination half-life (t1/2) for alfaxalone is approximately 25 minutes for a 2 mg/kg dose. Plasma clearance for a 2 mg/kg dose is 59.4 ± 12.9 mL/kg/min. (Product literature)
 ===Drug Interactions===
-Alfaxalone in cyclodextrin has been used safely after administration of an extremely wide range of premedication and peri-operative drugs.  Dose dependant CNS depression can be accentuated by administration of sedatives and analgesics.  Alfaxalone should not be administered concurrently with other intravenous anaesthetic induction drugs, but has been used safely as an induction agent prior to maintenance with halothane, isoflurane, sevoflurane and desflurane. It should not be mixed in the same syringe as other medications, as the cyclodextrin has a propensity to bind other chemicals.  If a need exists to dilute the alfaxalone in cyclodextrin solution, it has been shown to be stable in 0.9% Saline for up to 7 days.  Slight absorbtion to plastic of giving sets has been recognised, though this appears to be of no clinical significance.
+Alfaxalone in cyclodextrin has been used safely after administration of an extremely wide range of premedication and peri-operative drugs.  Dose dependent CNS depression can be accentuated by administration of sedatives and analgesics.  Alfaxalone should not be administered concurrently with other intravenous anaesthetic induction drugs, but has been used safely as an induction agent prior to maintenance with halothane, isoflurane, sevoflurane and desflurane. It should not be mixed in the same syringe as other medications, as the cyclodextrin has a propensity to bind other molecules.  If a need exists to dilute the alfaxalone in cyclodextrin solution, it has been shown to be stable in 0.9% Saline for up to 7 days.  Slight adsorption to plastic of giving sets has been recognised, though this appears to be of no clinical significance.
 ==Contraindications and Side Effects==

@@ Line 1: / Line 1: @@
 ==Introduction==
-The only available steroid anaesthetic for use in veterinary patients is '''alfaxalone'''. It is a progesterone derived ''neurosteroid''.
+The only available steroid anaesthetic for use in veterinary patients is '''alfaxalone''' (3-α-hydroxy-5-α-pregnane-11,20-dione). It is a progesterone derived ''neurosteroid''.
 ==Mechanism of Action==

@@ Line 15: / Line 15: @@
 ==Contraindications and Side Effects==
 ===Cardiovascular Effects===
-*At clinical doses, and employing the concepts of balanced anaesthesia, alfaxalone in cyclodextrin causes little cardiovascular effect, however a dose dependent decrease in arterial blood pressure thought to be due to myocardial contractility and stroke volume can be recognised at supra-clinical doses.
+*At clinical doses, and employing the concepts of balanced anaesthesia, alfaxalone in cyclodextrin causes little cardiovascular effect, however a dose dependent decrease in arterial blood pressure thought to be due to decreased myocardial contractility and stroke volume can be recognised at supra-clinical doses.
 ===Respiratory Effects===

@@ Line 18: / Line 18: @@
 ===Respiratory Effects===
-*Minimal respiratory effects.
+*Minimal respiratory effects. Rapid intravenous administration can produce a short period of apnoea, therefore when using the IV route alfaxalone should be administered steadily over a period of 60 seconds (e.g. 1/4 dose every 15 seconds) while assessing the depth of anaesthesia achieved.
 ===Other Effects===

@@ Line 21: / Line 21: @@
 ===Other Effects===
-*The combination product (alfaxalone/aldalone) solubilised in Cremohpor EL has been associated with histamine release leading to swollen paws and face, erythema and anaphylactoid reactions in dogs and cats, also making it contraindicated in cats with asthma or mast cell tumours.  This is not experienced with the aqueous cyclodextrin formulation of alfaxalone
+*Administration of the combination product (alfaxalone/aldalone) solubilised in Cremophor EL is associated with adverse effects. In cats hyperaemia or oedema of the ears and forepaws is observed in over half of animals; and in dogs it can induce an anaphylactoid reaction with histamine release leading to a fall in arterial blood pressure, urticaria and skin erythema. Its association with histamine release means it is contraindicated in animals with conditions such as asthma or mast cell tumours.
 ==Uses==

← Older revision		Revision as of 15:03, 1 September 2009
Line 1:		Line 1:
	{{unfinished}}		{{unfinished}}
		+	{{toplink
		+	\|linkpage =Anaesthesia
		+	\|linktext =Anaesthesia
		+	\|maplink= Anaesthesia Content Map - WikiClinical
		+	\|sublink1=Anaesthetic Drugs
		+	\|subtext1=Anaesthetic Drugs
		+	\|sublink2=Injectable Agents
		+	\|subtext2=Injectable Agents
		+	\|pagetype=Clinical
		+	}}
		+	<br>

	The only available steroid anaesthetic for use in veterinary patients is '''alfaxalone'''. It is a progesterone derived ''neurosteroid''.		The only available steroid anaesthetic for use in veterinary patients is '''alfaxalone'''. It is a progesterone derived ''neurosteroid''.